Onco-Innovations Enhances Polymer Testing for PNKP Inhibitor Development

Onco-Innovations Limited, based in Vancouver, has announced progress in its analytical methods for its PNKP Inhibitor Technology. The company has advanced the measurement of a critical polymer, crucial for its nanoparticle micelle delivery system. This development supports formulation and scale-up, vital as the company prepares for IND-enabling studies.

Utilizing refractive index detection with gel permeation chromatography (RI-GPC), Onco can assess polymer molecular weight and distribution, ensuring batch consistency. This analytical control aims to enhance formulation reproducibility, manufacturing scale-up, and reduce development risks ahead of regulatory and clinical stages.

RI-GPC is a standard tool for evaluating polymer quality, affecting nanoparticle behavior and scalability for clinical use. Strengthening this control fortifies the company's Chemistry, Manufacturing, and Controls package in preparation for regulatory review.